United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
|
2024-07-26 10:00:00 PM
|
Chg.
+1.8500
|
Volume |
Bid1:16:20 AM |
Ask1:16:20 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
338.2200USD
|
+0.55%
|
290,258
Turnover: 51.6 mill. |
329.5100Bid Size: 100 |
344.0000Ask Size: 200 |
15 bill.USD |
- |
16.08 |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
21.04 USD |
31.66% |
| EPS Diluted: |
19.81 USD |
32.07% |
| Revenues per Share: |
49.46 USD |
18.27% |
| Book Value per Share: |
127.18 USD |
22.76% |
| Cash Flow per Share: |
20.78 USD |
19.91% |
| Dividend per Share: |
- USD |
- |
| Total |
in mill. |
|
| Revenues: |
2,327.50 USD |
20.20% |
| Net Income: |
984.80 USD |
35.40% |
| Operating Cash Flow: |
978.00 USD |
- |
| Cash and Cash Equivalents: |
1,207.70 USD |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
16.08 |
10.45 |
| P/S Ratio: |
6.84 |
4.45 |
| P/BV ratio: |
2.66 |
1.73 |
| P/CF Ratio: |
16.27 |
10.58 |
| PEG: |
0.51 |
0.33 |
| Earnings Yield: |
6.22% |
9.57% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
15 bill. USD |
10.35 bill. USD |
| Free Float Market Cap.: |
- USD |
- USD |
| Market Cap. / Employee: |
- USD |
- USD |
| Shares Outstanding: |
44.36 mill. |
|
Profitability
| Gross Profit Margin: |
88.94% |
| EBIT Margin: |
50.91% |
| Net Profit Margin: |
42.31% |
| Return on Equity: |
16.46% |
| Return on Assets: |
13.74% |
Financial Strength
| Liquidity I / Cash Ratio: |
150.14% |
| Liquidity II / Quick Ratio: |
184.81% |
| Liquidity III / Current Ratio: |
441.45% |
| Debt / Equity Ratio: |
19.75% |
| Dynam. Debt / Equity Ratio: |
120.88% |
Efficiency
| Employees: |
- |
| Personal Expenses / Employee: |
- USD |
| Revenues / Employee: |
- USD |
| Net Income / Employee: |
- USD |
| Total Assets / Employee: |
- USD |
| * Fiscal Year End: |
2023-12-31 |
| Accounting Standard: |
US GAAP |
